Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether plinabulin (also known as BPI-2358) has an
effect on cancer and body in combination with nivolumab, a standard treatment for metastatic
squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy.
Plinabulin inhibits tumor growth by targeting both new and existing blood vessels going to
the tumor as well as killing tumor cells. Plinabulin is an investigational drug, a drug that
is not approved for use outside of research studies by regulatory agencies. Up to 38 patients
will be enrolled.